NCT02983006 2021-10-18Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaNYU Langone HealthPhase 1 Completed12 enrolled
NCT02076451 2019-02-12Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or LymphomasDaiichi SankyoPhase 1 Completed32 enrolled